Literature DB >> 15800936

BM18: A novel androgen-dependent human prostate cancer xenograft model derived from a bone metastasis.

Daniel R McCulloch1, Kenneth Opeskin, Erik W Thompson, Elizabeth D Williams.   

Abstract

BACKGROUND: Androgen-dependent prostate cancer (PrCa) xenograft models are required to study PrCa biology in the clinically relevant in vivo environment.
METHODS: Human PrCa tissue from a femoral bone metastasis biopsy (BM18) was grown and passaged subcutaneously through male severe combined immune-deficient (SCID) mice. Human mitochondria (hMt), prostate specific antigen (PSA), androgen receptor (AR), cytokeratin-18 (CK-18), pan-cytokeratin, and high molecular weight-cytokeratin (HMW-CK) were assessed using immunohistochemistry (IHC). Surgical castration was performed to examine androgen dependence. Serum was collected pre- and post-castration for monitoring of PSA levels.
RESULTS: BM18 stained positively for hMt, PSA, AR, CK-18, pan keratin, and negatively for HMW-CK, consistent with the staining observed in the original patient material. Androgen-deprivation induced tumor regression in 10/10 castrated male SCID mice. Serum PSA levels positively correlated with BM18 tumor size.
CONCLUSIONS: BM18 expresses PSA and AR, and rapidly regresses in response to androgen withdrawal. This provides a new clinically significant PrCa model for the study of androgen-dependent growth.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15800936     DOI: 10.1002/pros.20255

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  19 in total

Review 1.  Human prostate cancer heterotransplants: a review on this experimental model.

Authors:  Lluis A Lopez-Barcons
Journal:  Asian J Androl       Date:  2010-04-05       Impact factor: 3.285

Review 2.  Addressing Patient Specificity in the Engineering of Tumor Models.

Authors:  Laura J Bray; Dietmar W Hutmacher; Nathalie Bock
Journal:  Front Bioeng Biotechnol       Date:  2019-09-12

Review 3.  Patient-derived xenografts as in vivo models for research in urological malignancies.

Authors:  Takahiro Inoue; Naoki Terada; Takashi Kobayashi; Osamu Ogawa
Journal:  Nat Rev Urol       Date:  2017-02-21       Impact factor: 14.432

4.  Generation of Prostate Cancer Patient-Derived Xenografts to Investigate Mechanisms of Novel Treatments and Treatment Resistance.

Authors:  Hung-Ming Lam; Holly M Nguyen; Eva Corey
Journal:  Methods Mol Biol       Date:  2018

Review 5.  Drug discovery in prostate cancer mouse models.

Authors:  Kenneth C Valkenburg; Kenneth J Pienta
Journal:  Expert Opin Drug Discov       Date:  2015-06-01       Impact factor: 6.098

6.  Xenome--a tool for classifying reads from xenograft samples.

Authors:  Thomas Conway; Jeremy Wazny; Andrew Bromage; Martin Tymms; Dhanya Sooraj; Elizabeth D Williams; Bryan Beresford-Smith
Journal:  Bioinformatics       Date:  2012-06-15       Impact factor: 6.937

7.  Establishing prostate cancer patient derived xenografts: lessons learned from older studies.

Authors:  Pamela J Russell; Peter Russell; Christina Rudduck; Brian W C Tse; Elizabeth D Williams; Derek Raghavan
Journal:  Prostate       Date:  2015-01-05       Impact factor: 4.104

Review 8.  Serially heterotransplanted human prostate tumours as an experimental model.

Authors:  Lluis-A Lopez-Barcons
Journal:  J Cell Mol Med       Date:  2009-10-29       Impact factor: 5.310

9.  Elevated level of inhibin-alpha subunit is pro-tumourigenic and pro-metastatic and associated with extracapsular spread in advanced prostate cancer.

Authors:  P Balanathan; E D Williams; H Wang; J S Pedersen; L G Horvath; M G Achen; S A Stacker; G P Risbridger
Journal:  Br J Cancer       Date:  2009-05-12       Impact factor: 7.640

Review 10.  Mouse Models in Prostate Cancer Translational Research: From Xenograft to PDX.

Authors:  Domenica Rea; Vitale Del Vecchio; Giuseppe Palma; Antonio Barbieri; Michela Falco; Antonio Luciano; Davide De Biase; Sisto Perdonà; Gaetano Facchini; Claudio Arra
Journal:  Biomed Res Int       Date:  2016-05-18       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.